OncoMatch/Clinical Trials/NCT07247110
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Is NCT07247110 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pembrolizumab and Cetuximab for malignant neoplasm.
Treatment: MK-4716 · Pembrolizumab · Cetuximab — Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS alteration
Disease stage
Metastatic disease required
Prior therapy
Must have received: systemic therapy — locally advanced unresectable or metastatic disease
Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease
Cannot have received: immunotherapy
Exception: Arm MK-4716 + Pembrolizumab only; exclusion if discontinued from prior immunotherapy
Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute of New Jersey ( Site 0052) · New Brunswick, New Jersey
- NEXT Oncology ( Site 0051) · Irving, Texas
- NEXT Virginia ( Site 0054) · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify